ZYDUSLIFE IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
| CUSTOMER | BASIS | EST ₹CR | RANGE | % REV | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| China. | UNSTATED | 24,434 | 15,963–24,434 | 90.0% | — | FY26 | EST | 75% |
| “During the year, the JV strengthened its presence through its first product supplies to China and expanded its portfolio in India with the launch of three mole…” AR DOC | ||||||||
| Financial Year | UNSTATED | 24,434 | 15,963–24,434 | 90.0% | — | FY26 | EST | 75% |
| “Zydus Pharmaceuticals USA Inc., USA (a wholly owned subsidiary company) Supply and Distribution Agreement On-going Pricing of supply of products based on relev…” AR · +1 DOC | ||||||||
| Others | CONTRACT | 24,434 | 15,963–24,434 | 90.0% | — | FY26 | EST | 75% |
| “Less: Allowances for credit impaired 201 193 909 1,015 Export Incentive Receivables 111 41 Prepaid Expenses 480 523 Advance CSR contribution [Refer Note-37] 28…” AR · +2 DOC | ||||||||
| Deputy Commissioner | CONTRACT | 24,434 | 15,963–24,434 | 90.0% | — | FY25 | EST | 75% |
| “Updates Zydus Lifesciences Limited has informed the Exchange regarding 'Receipt of Order-In-Original from Deputy Commissioner ST, Special Circle-VJA1: Vijayawa…” ANN · 30-AUG-24 · +1 DOC | ||||||||
| Deputy Commissioner of State Tax | CONTRACT | 24,434 | 15,963–24,434 | 90.0% | — | FY25 | EST | 75% |
| “Updates Zydus Lifesciences Limited has informed the Exchange regarding 'Receipt of Order-In-Original by Zydus Healthcare Limited from Deputy Commissioner of St…” ANN · 30-AUG-24 DOC | ||||||||
| Assistant Commissioner | CONTRACT | 24,434 | 15,963–24,434 | 90.0% | — | FY25 | EST | 75% |
| “Updates Zydus Lifesciences Limited has informed the Exchange regarding 'Receipt of Order-In-Original by Zydus Healthcare Limited from Assistant Commissioner, S…” ANN · 29-AUG-24 DOC | ||||||||
| Joint Commissioner | CONTRACT | 24,434 | 15,963–24,434 | 90.0% | — | FY25 | EST | 75% |
| “Updates Zydus Lifesciences Limited has informed the Exchange regarding 'Receipt of Order-In-Original from Joint Commissioner, Corporate Circle, Ghaziabad-I, Ut…” ANN · 28-AUG-24 DOC | ||||||||
| PFIZERPfizer Ltd. | UNSTATED | 24,434 | 15,963–24,434 | 90.0% | — | FY26 | EST | 70% |
| “Zydus Hospira Oncology Pvt. Ltd. Zydus Hospira Oncology Pvt. Ltd. is a 50:50 contract manufacturing JV between the Company and Hospira Inc., USA (now part of P…” AR · +1 DOC | ||||||||
| Securities and Exchange Board of India | UNSTATED | 24,434 | 15,963–24,434 | 90.0% | — | FY26 | EST | 70% |
| “f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with…” AR · +1 DOC | ||||||||
| Authority. | UNSTATED | 24,434 | 15,963–24,434 | 90.0% | — | FY26 | EST | 70% |
| “The said requirement does not apply to shares in respect of which there is a specific order of Court, Tribunal or Statutory Authority, restraining any transfer…” AR · +1 DOC | ||||||||
| Superintendent | CONTRACT | 24,434 | 15,963–24,434 | 90.0% | — | FY25 | EST | 65% |
| “Updates Zydus Lifesciences Limited has informed the Exchange regarding 'Receipt of Order-In-Original from Superintendent, Jurisdiction: CUTTACK IV RANGE: CUTTA…” ANN · 30-AUG-24 DOC | ||||||||
| Zydus Healthcare Limited | CONTRACT | 24,434 | 15,963–24,434 | 90.0% | — | FY25 | EST | 65% |
| “Updates Zydus Lifesciences Limited has informed the Exchange regarding 'Receipt of order by Zydus Healthcare Limited, a wholly owned subsidiary company, on the…” ANN · 08-AUG-24 DOC | ||||||||
| State Tax Officer | CONTRACT | 24,434 | 15,963–24,434 | 90.0% | — | FY25 | EST | 65% |
| “Updates Zydus Lifesciences Limited has informed the Exchange regarding 'Receipt of an order from State Tax Officer, M S Kutch, Div-12, Gandhidham'.” ANN · 26-JUL-24 DOC | ||||||||
| Excise and Taxation Officer-cum-State Tax Officer | CONTRACT | 24,434 | 15,963–24,434 | 90.0% | — | FY24 | EST | 65% |
| “Updates Zydus Lifesciences Limited has informed the Exchange regarding 'Demand order received from Excise And Taxation Officer-cum-State Tax Officer, Punjab'.” ANN · 12-MAR-24 DOC | ||||||||
| CCLCCL Products (I) Ltd. | UNSTATED | 3,525 | 2,303–3,525 | 13.0% | — | 2025-11 | EST | 50% |
| “CCL does enjoy very strong brand recognition and high customer loyalty and retention, and we believe that this product portfolio and business is strongly posit…” CONCALL DOC | ||||||||
| BANKINDIABank of India | UNSTATED | 631 | 412–631 | 2.3% | — | FY26 | EST | 75% |
| “He has served on the Central Board of the Reserve Bank of India and has held leadership positions across several prominent national institutions, educational b…” AR DOC | ||||||||
| CDSLCentral Depository Services (India) Ltd. | UNSTATED | 4 | 3–4 | 0.0% | — | FY26 | EST | 60% |
| “Now enter your User ID a. For CDSL: 16 digits beneficiary ID, (e.g. if your beneficiary ID is 12**************, then your user ID is 12************** b. For NS…” AR · +1 DOC | ||||||||
| TORNTPHARMTorrent Pharmaceuticals Ltd. | UNSTATED | — | — | — | R&D | FY26 | EST | 75% |
| “Licensing and Supply Entered into licensing and supply agreements with Torrent Pharmaceuticals and Lupin Ltd. for the co-marketing of Semaglutide Injection, ex…” AR DOC | ||||||||
| LUPINLupin Ltd. | UNSTATED | — | — | — | R&D | FY26 | EST | 75% |
| “Licensing and Supply Entered into licensing and supply agreements with Torrent Pharmaceuticals and Lupin Ltd. for the co-marketing of Semaglutide Injection, ex…” AR · +1 DOC | ||||||||
| Financial Year | UNSTATED | — | — | — | SG&A | FY25 | EST | 70% |
| “Number of consumer complaints FY 2024-25 Current Financial Year FY 2023-24 Previous Financial Year Received during the year Pending resolution at the end of ye…” AR · +1 DOC | ||||||||
| Others | UNSTATED | — | — | — | R&D | FY26 | EST | 70% |
| “The carrying amount of goodwill has been allocated as follows: ` in Million As at March 31, 2026 As at March 31, 2025 Consumer Wellness [Refer Note-54 A and B]…” AR DOC | ||||||||
| Authority. | UNSTATED | — | — | — | COGS | FY26 | EST | 70% |
| “A Contingent Liabilities: a Claims against the Group not acknowledged as debts 398 403 b Other money for which the Group is contingently liable: i In respect o…” AR · +1 DOC | ||||||||
| Torrent | UNSTATED | — | — | — | R&D | 2026-05 | EST | 65% |
| “To expand patient access to these advanced diabetes and weight management therapies, we also entered licensing and supply agreements with Lupin and Torrent Pha…” CONCALL DOC | ||||||||
| SUPPLIER | BASIS | EST ₹CR | RANGE | % COST | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| FORCEMOTForce Motors Ltd. | UNSTATED | 8,151 | 4,483–8,151 | 99.7% | — | FY26 | EST | 75% |
| “Mr. Mukesh Mangalbhai Patel also serves as Director on the Boards of Zydus Lifesciences Limited, Jade Blue Lifestyle India Limited, Desai Brothers Ltd, Gulmoha…” AR DOC | ||||||||
| Financial Year | UNSTATED | — | — | — | COGS | FY25 | EST | 75% |
| “Percentage of input material (inputs to total inputs by value) sourced from suppliers: FY 2024-2025 Current Financial Year FY 2023-2024 Previous Financial Year…” AR · +1 DOC | ||||||||
| LUPINLupin Ltd. | UNSTATED | — | — | — | R&D | FY26 | EST | 75% |
| “We also entered into a licensing and supply agreement with Zydus Lifesciences to co-market an innovative semaglutide injection in India.” AR DOC | ||||||||
| Others | UNSTATED | — | — | — | COGS | FY26 | EST | 70% |
| “Details on assessment of value chain partners: % of value chain partners (by value of business done with such partners) that were assessed Child labour 39%* Fo…” AR · +1 DOC | ||||||||
| SOURCE | READ | % | LAST READ |
|---|---|---|---|
| ANNOUNCEMENTS | 9/9 | 100% | 07-NOV-26 |
| ANNUAL | 2/2 | 100% | 15-OCT-26 |
| CONCALL | 5/5 | 100% | 08-NOV-26 |
| ORDERS | 9/9 | 100% | 07-NOV-26 |
| RATINGS | 0/1 | 0% | — |
| SCREENER | 1/1 | 100% | 08-NOV-26 |
| SIGNAL | VALUE | AS OF | INPUTS |
|---|---|---|---|
| CUSTOMER HHI | 0.746 | 15-NOV-26 | Bank of India share 2% · Pfizer Ltd. share 85% · Central Depository Services (India) Ltd. share 0% · CCL Products (I) Ltd. share 12% |
| CUST MOM 1M | +0.7% | 15-NOV-26 | from 16-OCT-26 · Torrent Pharmaceuticals Ltd. +2.4% w 0 · Lupin Ltd. +1.0% w 0 · Bank of India +16.4% w 0 · Pfizer Ltd. +0.9% w 1 · Central Depository Services (India) Ltd. +12.4% w 0 · CCL Products (I) Ltd. -3.0% w 0 |
| SUPP MOM 1M | +10.7% | 15-NOV-26 | from 16-OCT-26 · Lupin Ltd. +1.0% w 0 · Force Motors Ltd. +10.7% w 1 |